HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLOUDBREAK-B

1.190

0.000

Volume:- -

Turnover:- -

Market Cap:1.10B

PE:-11.55

High:1.190

Open:1.190

Low:1.190

Close:1.190

52wk High:9.580

52wk Low:0.900

Shares:925.00M

HK Float Shares:925.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.103

ROE:--

ROA:-190.68%

PB:3.34

PE(LYR):-11.55

PS:521.83

Loading ...

Overview Company News Filings

Cloudbreak Pharma Inc - FDA Completes Safety Review of Cbt-199 Ind Application; Clinical Investigation May Proceed

THOMSON REUTERS

Cloudbreak Pharma Completes HK$48.00 Million Fund Redemption, Booking HK$0.88 Million Gain

Bulletin Express

Cloudbreak Pharma Inc - Redeems Fund in Full, Receives HK$48.0 Mln, Records HK$0.88 Mln Gain, 2.53% Annualised Return

THOMSON REUTERS

Cloudbreak Pharma redeems fund after use-of-proceeds non-compliance issue

Cloudbreak Pharma to present MKI platform at Eyecelerator @ ARVO 2026

Here's Why We're Watching Cloudbreak Pharma's (HKG:2592) Cash Burn Situation

Simply Wall St.

CLOUDBREAK-B Allocates 1.785 Million Shares

Cloudbreak Pharma files HKEX next-day return for 1,785,000 shares at HKD 0

Cloudbreak Pharma publishes 2025 annual report

Cloudbreak Pharma Releases First ESG Report: Sets 2027 Resource-Efficiency Targets and Reports 2025 GHG Emissions of 533.06 tCO₂e

Bulletin Express

CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million

Cloudbreak Pharma FY25 net loss narrows to US$ 68 million; revenue posts no revenue

CLOUDBREAK-B Flags Temporary Deviation in IPO Funds; Redeems HK$47.10 Million Investment in North Rock Fund

Bulletin Express

Cloudbreak Pharma redeems HK$47 million fund after Hong Kong listing rules breach

CLOUDBREAK-B Shares Drop Over 6% to Record Low Following Withdrawal of CBT-009 Clinical Trial Application

CLOUDBREAK-B (02592) Voluntarily Withdraws China IND for CBT-009; Other Core Pipelines Stay on Track

Bulletin Express

CLOUDBREAK-B Withdraws CBT-009 New Drug Trial Application to Reassess Clinical Strategy

Cloudbreak Pharma withdraws CBT-009 IND application for possible Phase 3 trial in China

Cloudbreak Pharma - Expects Phase 3 Mrct Completion for Cbt-001 in Q3 2026

THOMSON REUTERS

Cloudbreak Pharma Inc - to Reassess Clinical Development Strategy for Cbt-009

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/02592/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":1.19,"timestamp":1789003225948,"preClose":1.19,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":925000000,"shares":925000000,"eps":-0.103023,"marketStatus":"Halted","change":0,"latestTime":"09-10 09:20:25","open":1.19,"high":1.19,"low":1.19,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.024,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":0,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.19,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":925000000,"roa":"-190.68%","roe":"--","lyrEps":-0.103023,"shares":925000000,"dividePrice":0,"high":1.19,"amplitude":0,"preClose":1.19,"low":1.19,"week52Low":0.9,"pbRate":"3.34","psRate":"521.83","week52High":9.58,"institutionHeld":0,"latestPrice":1.19,"eps":-0.103023,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.024,"open":1.19,"prevYearClose":5.2,"prevWeekClose":1.18,"prevMonthClose":1.145,"prevQuarterClose":1.56,"fiveDayClose":1.155,"twentyDayClose":1.18,"sixtyDayClose":1.18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-30","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2026-09-09","current":-1.162109,"percent":0.979452,"low":-24.505522,"twenty":-11.842125,"median":-5.592845,"eighty":-2.069994,"high":-1.021022,"avg":-6.569605,"sd":4.940984,"marketCap":1005033411},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218},{"date":"2025-11-21","current":-12.23865,"twenty":-12.234818,"median":-6.500592,"eighty":-5.630174,"marketCap":3984741151},{"date":"2025-11-28","current":-21.343443,"twenty":-12.412307,"median":-6.613869,"eighty":-5.677994,"marketCap":6946032996},{"date":"2025-12-05","current":-20.614529,"twenty":-12.626633,"median":-6.790202,"eighty":-5.718633,"marketCap":6711142992},{"date":"2025-12-12","current":-17.961539,"twenty":-12.716498,"median":-11.142834,"eighty":-5.735493,"marketCap":5847083331},{"date":"2025-12-19","current":-14.819321,"twenty":-12.837409,"median":-11.27102,"eighty":-5.75741,"marketCap":4823634025},{"date":"2025-12-24","current":-14.055026,"twenty":-12.984934,"median":-11.600706,"eighty":-5.767869,"marketCap":4571966163},{"date":"2026-01-02","current":-11.620216,"twenty":-12.995771,"median":-11.729724,"eighty":-5.769371,"marketCap":3783406861},{"date":"2026-01-09","current":-7.540769,"twenty":-12.961935,"median":-11.510378,"eighty":-5.972321,"marketCap":2457956120},{"date":"2026-01-16","current":-8.049692,"twenty":-12.941587,"median":-11.169175,"eighty":-5.988337,"marketCap":2625734695},{"date":"2026-01-23","current":-6.609576,"twenty":-12.863288,"median":-10.620058,"eighty":-5.996682,"marketCap":2155954686},{"date":"2026-01-30","current":-6.294491,"twenty":-12.820156,"median":-9.452561,"eighty":-6.004685,"marketCap":2055287541},{"date":"2026-02-06","current":-5.800172,"twenty":-12.797534,"median":-8.075865,"eighty":-6.004685,"marketCap":1895897895},{"date":"2026-02-13","current":-5.772062,"twenty":-12.788929,"median":-7.957902,"eighty":-5.976779,"marketCap":1887508966},{"date":"2026-02-20","current":-5.722622,"twenty":-12.762909,"median":-7.89408,"eighty":-5.899654,"marketCap":1870731109},{"date":"2026-02-27","current":-5.716309,"twenty":-12.718958,"median":-7.540769,"eighty":-5.819712,"marketCap":1870731109},{"date":"2026-03-06","current":-5.592845,"twenty":-12.7039,"median":-6.802294,"eighty":-5.77076,"marketCap":1828786465},{"date":"2026-03-13","current":-5.252211,"twenty":-12.674344,"median":-6.763399,"eighty":-5.752368,"marketCap":1719730391},{"date":"2026-03-20","current":-4.787506,"twenty":-12.644727,"median":-6.625153,"eighty":-5.711698,"marketCap":1568729674},{"date":"2026-03-27","current":-4.279308,"twenty":-12.631386,"median":-6.530805,"eighty":-5.600393,"marketCap":1400951099},{"date":"2026-04-02","current":-4.3756,"twenty":-12.611231,"median":-6.512878,"eighty":-5.567465,"marketCap":1434506814},{"date":"2026-04-10","current":-4.248889,"twenty":-12.593551,"median":-6.499576,"eighty":-5.532786,"marketCap":1392562170},{"date":"2026-04-17","current":-3.434267,"twenty":-12.529717,"median":-6.439136,"eighty":-5.502771,"marketCap":1124116451},{"date":"2026-04-24","current":-3.028108,"twenty":-12.499065,"median":-6.412742,"eighty":-5.465751,"marketCap":1604675194},{"date":"2026-04-30","current":-2.35827,"twenty":-12.455796,"median":-6.350281,"eighty":-5.436669,"marketCap":1249957520},{"date":"2026-05-08","current":-2.422963,"twenty":-12.412307,"median":-6.306537,"eighty":-5.348441,"marketCap":1283740155},{"date":"2026-05-15","current":-2.215232,"twenty":-12.362936,"median":-6.237324,"eighty":-5.224545,"marketCap":1173946589},{"date":"2026-05-22","current":-2.103037,"twenty":-12.335851,"median":-6.187936,"eighty":-5.079251,"marketCap":1114826977},{"date":"2026-05-29","current":-2.055189,"twenty":-12.29622,"median":-6.159956,"eighty":-4.693687,"marketCap":1089490000},{"date":"2026-06-05","current":-1.943602,"twenty":-12.236095,"median":-6.134636,"eighty":-4.452767,"marketCap":1030370388},{"date":"2026-06-12","current":-2.070618,"twenty":-12.215803,"median":-6.134042,"eighty":-4.302022,"marketCap":1097935659},{"date":"2026-06-18","current":-1.863414,"twenty":-12.1843,"median":-6.080141,"eighty":-4.208883,"marketCap":988142093},{"date":"2026-06-26","current":-1.607919,"twenty":-12.150518,"median":-6.004708,"eighty":-3.379693,"marketCap":853011550},{"date":"2026-07-03","current":-2.053171,"twenty":-12.124388,"median":-5.992509,"eighty":-2.739542,"marketCap":1089490000},{"date":"2026-07-10","current":-2.134398,"twenty":-12.109822,"median":-5.972321,"eighty":-2.532616,"marketCap":1131718295},{"date":"2026-07-17","current":-2.101828,"twenty":-11.973906,"median":-5.886479,"eighty":-2.422963,"marketCap":1114826977},{"date":"2026-07-24","current":-2.069578,"twenty":-11.968515,"median":-5.84391,"eighty":-2.309668,"marketCap":1097935659},{"date":"2026-07-31","current":-1.862057,"twenty":-11.947093,"median":-5.798666,"eighty":-2.247923,"marketCap":988142093},{"date":"2026-08-07","current":-1.925288,"twenty":-11.910048,"median":-5.770977,"eighty":-2.212119,"marketCap":1021924729},{"date":"2026-08-14","current":-1.869116,"twenty":-11.882099,"median":-5.767494,"eighty":-2.165101,"marketCap":992364923},{"date":"2026-08-21","current":-1.909914,"twenty":-11.871403,"median":-5.723964,"eighty":-2.134253,"marketCap":1013479070},{"date":"2026-08-28","current":-1.839188,"twenty":-11.868929,"median":-5.708624,"eighty":-2.114609,"marketCap":975473605},{"date":"2026-09-04","current":-1.052314,"twenty":-11.849329,"median":-5.61954,"eighty":-2.086117,"marketCap":996587752},{"date":"2026-09-09","current":-1.061005,"twenty":-11.842125,"median":-5.592845,"eighty":-2.069994,"marketCap":1005033411}],"updateTime":1789021584525},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2631668639","title":"Cloudbreak Pharma Inc - FDA Completes Safety Review of Cbt-199 Ind Application; Clinical Investigation May Proceed","url":"https://stock-news.laohu8.com/highlight/detail?id=2631668639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631668639?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:37","pubTimestamp":1777538249,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136105724","title":"Cloudbreak Pharma Completes HK$48.00 Million Fund Redemption, Booking HK$0.88 Million Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=1136105724","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136105724?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:03","pubTimestamp":1776862995,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B) has fully redeemed its investment in an offshore fund, receiving HK$48.00 million in proceeds and realizing a HK$0.88 million gain, equivalent to an annualised...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049285","title":"Cloudbreak Pharma Inc - Redeems Fund in Full, Receives HK$48.0 Mln, Records HK$0.88 Mln Gain, 2.53% Annualised Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049285?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:42","pubTimestamp":1776861766,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN415089:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049287","title":"Cloudbreak Pharma redeems fund after use-of-proceeds non-compliance issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049287","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049287?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:42","pubTimestamp":1776861765,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma redeemed an investment fund in full to address a compliance issue tied to a temporary deviation from its IPO use-of-proceeds plan.Cloudbreak booked a gain of about HK$880,000 on the exit, implying an annualized return of about 2.5%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6lW4r0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629466160","title":"Cloudbreak Pharma to present MKI platform at Eyecelerator @ ARVO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629466160","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629466160?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:09","pubTimestamp":1776859749,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma will present its multi-kinase inhibition platform at Eyecelerator @ ARVO 2026 on May 1, 2026, in Denver.Presentation, titled “Multi-Kinase Inhibition: A New Focus for the Anterior Segment,” is scheduled for 1:36-1:41 pm MDT.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLb99qsv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4585","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","02592","SG9999014039.USD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","BK1161","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628476835","title":"Here's Why We're Watching Cloudbreak Pharma's (HKG:2592) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628476835","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628476835?lang=en_us&edition=fundamental","pubTime":"2026-04-19 08:11","pubTimestamp":1776557481,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/heres-why-were-watching-cloudbreak-pharmas-hkg2592-cash-burn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/heres-why-were-watching-cloudbreak-pharmas-hkg2592-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144898650","title":"CLOUDBREAK-B Allocates 1.785 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1144898650","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144898650?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:38","pubTimestamp":1775558289,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on April 3, 2026, the company allotted and issued 1.785 million shares under the 2023 Equity Incentive Plan.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625931527","title":"Cloudbreak Pharma files HKEX next-day return for 1,785,000 shares at HKD 0","url":"https://stock-news.laohu8.com/highlight/detail?id=2625931527","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625931527?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:09","pubTimestamp":1775556581,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma filed a next day disclosure return reporting issuance of 1,785,000 new ordinary shares on April 3, 2026 under its 2023 equity incentive scheme.Issued shares outstanding rose to 851,907,081 from 850,122,081.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLbcC9tC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595715","title":"Cloudbreak Pharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624595715?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:32","pubTimestamp":1774996355,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma annual report for 2025 highlighted progress toward a commercial-stage transition following July 2025 Hong Kong listing that raised net proceeds of about HK$500 million.Lead asset CBT-001 for pterygium completed Phase 3 global enrollment in May 2025 with 660 patients, with top-line data expected in 2026.Pipeline focus broadened with CBT-199 for presbyopia entering clinical stage in December 2025, with FDA IND review ending without a clinical hold.CBT-009 pediatric myopia program advanced with FDA IND filing, with China Phase 3 plans reset following voluntary withdrawal of PRC IND to manage development risk.Management reiterated target for first product launch in 2027, with business development aimed at adding 1-2 new regional licensing deals in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbtWjV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127781440","title":"Cloudbreak Pharma Releases First ESG Report: Sets 2027 Resource-Efficiency Targets and Reports 2025 GHG Emissions of 533.06 tCO₂e","url":"https://stock-news.laohu8.com/highlight/detail?id=1127781440","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127781440?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:04","pubTimestamp":1774969470,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma published its inaugural Environmental, Social and Governance Report, detailing 2025 performance metrics, governance arrangements and mid-term sustainability goals. Key takeaways...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134093030","title":"CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1134093030","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134093030?lang=en_us&edition=fundamental","pubTime":"2026-03-31 01:44","pubTimestamp":1774892659,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04%...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623534121","title":"Cloudbreak Pharma FY25 net loss narrows to US$ 68 million; revenue posts no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2623534121","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623534121?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:08","pubTimestamp":1774883325,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma posted a net loss of US$ 68 million for fiscal 2025, narrowing from the prior year.Revenue fell to no revenue from US$ 10 million a year earlier.Operating loss widened to US$ 107 million, pressured by higher general and administrative spending and research and development expenses.Cash and cash equivalents rose to US$ 40 million, while total assets climbed to US$ 67 million.Phase 3 recruitment for lead candidate CBT-001 completed with 660 patients, with initial efficacy and safety data expected later in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6xLhFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146526112","title":"CLOUDBREAK-B Flags Temporary Deviation in IPO Funds; Redeems HK$47.10 Million Investment in North Rock Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=1146526112","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146526112?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:06","pubTimestamp":1774883179,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B) announced that HK$47.10 million of its June 2025 IPO proceeds were placed into North Rock Fund SPC on 3 July 2025, a move later deemed inconsistent with the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623411843","title":"Cloudbreak Pharma redeems HK$47 million fund after Hong Kong listing rules breach","url":"https://stock-news.laohu8.com/highlight/detail?id=2623411843","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623411843?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:01","pubTimestamp":1774882867,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma flagged a compliance breach tied to use of proceeds from fiscal 2025 IPO, citing a temporary deviation from prospectus allocation.HKD 47 million of net proceeds funded a July 3, 2025 subscription in North Rock Fund SPC, later classified as fair-value financial assets rather than cash equivalents.Board ordered immediate redemption, sending request on March 30, 2026; fund processing redemption as of announcement date.Transaction met Hong Kong Listing Rules threshold for a discloseable transaction, triggering reporting and announcement requirements that were not met on time.Company tightened controls via staff recirculation of procedures, compliance training, enhanced consultation with legal, audit, compliance advisers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL83DyKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190155750","title":"CLOUDBREAK-B Shares Drop Over 6% to Record Low Following Withdrawal of CBT-009 Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1190155750","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190155750?lang=en_us&edition=fundamental","pubTime":"2026-03-20 10:40","pubTimestamp":1773974424,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) fell more than 6%, hitting a low of HK$1.82, marking a new record low since its listing. As of the time of writing, the stock was down 6.09% to HK$1.85, with a turnover of...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4090","BK4588","02592","VXUS","CBT","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199098192","title":"CLOUDBREAK-B (02592) Voluntarily Withdraws China IND for CBT-009; Other Core Pipelines Stay on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=1199098192","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199098192?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:22","pubTimestamp":1773919373,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B, 02592) has voluntarily withdrawn its Investigational New Drug (IND) application in China for CBT-009, an SFA+ atropine ophthalmic emulsion aimed at treating...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153174165","title":"CLOUDBREAK-B Withdraws CBT-009 New Drug Trial Application to Reassess Clinical Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1153174165","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153174165?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:18","pubTimestamp":1773919116,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) has announced that it has decided to voluntarily withdraw its existing New Drug Clinical Trial Application (NDCTA) for CBT-009 ophthalmic emulsion. CBT-009 is an atropine eye...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090","02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244343","title":"Cloudbreak Pharma withdraws CBT-009 IND application for possible Phase 3 trial in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244343","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244343?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:02","pubTimestamp":1773918177,"startTime":"0","endTime":"0","summary":"Cloudbreak withdrew its Investigational New Drug application for CBT-009 in China after concluding it may be difficult to include China in a placebo-controlled multi-regional Phase 3 trial due to differing regional regulatory requirements.Management said it will reassess the clinical development strategy for CBT-009 and may hold further pre-submission consultations with the Center for Drug Evaluation or resubmit a clinical studies application after supplementary studies or protocol adjustments.The R&D and IND application status of other core products CBT-004 and CBT-199 remains on track, and Phase 3 MRCT for CBT-001 is expected to be completed in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL72k6c8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620318244","title":"Cloudbreak Pharma - Expects Phase 3 Mrct Completion for Cbt-001 in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620318244","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620318244?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:01","pubTimestamp":1773918093,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4070RS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620244874","title":"Cloudbreak Pharma Inc - to Reassess Clinical Development Strategy for Cbt-009","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244874?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:01","pubTimestamp":1773918093,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4070RS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":64,"code":"91000000","status":"200"}]}}